The NEAT study is a clinical trial sponsored by the University of California Cures for Alzheimer’s Initiative grant, focusing on nicotinamide, a dissolving form of vitamin B3. It is taking place at two University of California Alzheimer’s research centers (UCLA & UC Irvine).
The 12-month study is investigating the safety and tolerability of a daily high dose of oral nicotinamide, determining if it can reduce levels of tau found in spinal fluid. Tau is one of the brain proteins associated with Alzheimer’s disease.
The study also measures whether nicotinamide is effective in reducing cognitive decline. This study is for individuals already diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Other requirements also apply. Participants will have a 50 percent chance of receiving the study drug or an inactive substance known as a placebo.